NCT02970162View on ClinicalTrials.gov

Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)

PHASE3CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Lambert-Eaton Myasthenic Syndrome
Interventions
DRUG

Amifampridine Phosphate

DRUG

Placebo Oral Tablet

Trial Locations (1)

90095

UCLA, Los Angeles

Sponsors
All Listed Sponsors
lead

Catalyst Pharmaceuticals, Inc.

INDUSTRY

NCT02970162 - Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) | Biotech Hunter | Biotech Hunter